Skip to main content

View full-text article in PMC

. 2022 Jan 24;12:1248. doi: 10.1038/s41598-022-05193-z

Table 2.

Comparison of PDX tumor growth rates between groups.

Model	p-value
Model	ANOVA	Selumetinib vs vehicle	KRT-232 vs vehicle	Combination vs vehicle	KRT-232 vs selumetinib	Combination vs selumetinib	Combination vs KRT-232
C1035	*<0.001*	0.650	0.903	*<0.001*	0.961	*0.001*	*<0.001*
B1011	*<0.001*	*0.027*	0.610	*<0.001*	0.298	*0.043*	*0.001*
C1185	0.052	0.688	0.988	0.071	0.861	0.464	0.134
C1114	*<0.001*	*<0.001*	*0.014*	*<0.001*	*0.026*	*<0.001*	*<0.001*
PDX.004	*0.002*	0.060	0.137	*<0.001*	0.976	*0.050*^a	*0.020*
PDX.008	*<0.001*	*<0.001*	0.003	*<0.001*	*<0.001*	*<0.001*	*<0.001*
PDX.020	*<0.001*	*0.030*	0.043	*<0.001*	0.998	*0.015*	*0.010*

p-values < 0.05 were regarded as significant and are shown in bold italics.

^aThe p-value was 0.0495.